Chronic Obstructive Pulmonary Disease (COPD)

Description

Verona's inhaled dual-action PDE inhibitor ensifentrine has the potential to be paradigm changing, but what barriers do KOLs identify that could hinder its uptake? Where do experts see Sanofi/Regeneron's anti-IL4/IL13 mAb Dupixent delivering value? Why, despite failure of prior Phase III studies, are KOLs are optimistic about anti-IL5 mAbs - GSK's Nucala and AstraZeneca's Fasenra? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Executive summary (10)

Treatment algorithm

Research objectives (9)

ICS/LABA/LAMA triple combination therapies (21)

Marketed therapies (21)
- Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK) (5)
- Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi) (11)
- Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca) (5)

Biological therapies (62)

Anti-IL5 pipeline therapies (15)
- Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (15)

Anti-IL4/IL13 pipeline therapies (11)
- Dupixent (dupilumab; Regeneron/Sanofi) (11)

Anti-TSLP pipeline therapies (8)
- Tezspire (tezepelumab; Amgen/AstraZeneca) (8)

Anti-IL33 pipeline therapies (28)
- Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi) (10)
- Astegolimab (RG6149; Roche) (10)
- Tozorakimab (MEDI3506; AstraZeneca) (8)